All In Biotech

Drug Trial Radar · NCT05590403

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults ≥60 Years of Age

Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,544 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,544

Actual

Start

Oct 28, 2022

Primary completion

Mar 13, 2023

Study completion Feb 12, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at increased risk (AIR) of respiratory syncytial virus (RSV)-lower respiratory tract disease (LRTD), versus adults \>=60 YOA

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    One dose administered intramuscularly at Day 1.

  • PlaceboDrug

    One dose administered intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
  2. RSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)
  3. RSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
  4. RSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)
  5. RSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31)
  6. RSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)
  7. RSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
  8. RSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV GroupTime frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.